TruBridge, Inc. (TBRG) Q2 2025 Earnings Call Transcript

TruBridge (TBRG) reported Q2 2025 results featuring strong bookings of $25.6 million TCV, though revenue of $85.7 million landed at the lower end of expectations, primarily due to slightly elevated CBO client attrition and delayed revenue recognition from larger, longer-implementation deals. Despite this, adjusted EBITDA reached $13.7 million (16% margin), exceeding the midpoint, driven by significant efficiency gains from global offshoring, resource management, and a favorable revenue mix. Consequently, full-year revenue guidance was narrowed to $345M-$350M, while adjusted EBITDA guidance was raised to $62M-$67M, reflecting an increased focus on profitability and operational improvements, including establishing a physical presence in India, new leadership hires, and AI integration.

Analysis

TruBridge (TBRG) presented a mixed but strategically coherent Q2 2025, characterized by a deliberate focus on profitability at the expense of near-term revenue growth. While revenue of $85.7 million was at the low end of expectations, this was offset by adjusted EBITDA of $13.7 million (a 16% margin), which exceeded the midpoint. This trade-off is reflected in the revised full-year guidance, which lowers the top end of the revenue range to $345M-$350M while raising the adjusted EBITDA forecast to $62M-$67M. The revenue pressure stems from two main factors: slightly elevated client attrition in the Central Billing Office (CBO) business as the company refines its offshore operations, and delayed revenue recognition from larger, more complex contract wins. The company is actively addressing the retention issue with new leadership and a plan to establish a physical office in India by 2026 to improve standardization and training. Simultaneously, the improved profitability is being driven by significant operational efficiencies, including cost optimization, enhanced resource management, and a favorable revenue mix from its overperforming encoder solution. The balance sheet strengthened, with net leverage reduced to 2.4x from 3.9x a year ago, and robust bookings of $25.6 million TCV suggest healthy underlying demand, even if the revenue impact is deferred.

Key Decisions for Investors

• Investors should prioritize adjusted EBITDA and free cash flow metrics over near-term revenue, as the company is clearly executing a strategy of profitable growth even at the expense of temporary top-line softness.
• Closely monitor the CBO client retention rate and management's progress on its offshore operational overhaul, as renewed client stability is the primary catalyst for revenue to re-accelerate in 2026.
• Given the six-month implementation lag for larger contracts, treat the strong TCV bookings figure of $25.6 million as a more reliable forward-looking indicator of business health than near-term revenue performance.
• Consider the announced partnership with Microsoft for AI integration as a positive catalyst for long-term product differentiation and competitiveness, particularly in attracting and retaining clients in the community and rural healthcare market.